Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Sales 4 860 5 872 6 711 7 782 8 342 8 800
EBITDA 1 435 2 732 3 110 3 440 3 845 4 013
Operating profit (EBIT) 1 331 2 080 2 534 2 283 2 894 2 829
Pre-Tax Profit (EBT) 1 330 2 079 2 554 2 360 3 023 2 951
Net income 896 1 199 2 444 2 002 2 521 2 558
P/E ratio 47,7x 36,4x 17,5x 19,7x 15,7x 15,5x
EPS ( $ ) 7,70 10,3 21,3 17,5 21,9 22,2
Dividend per Share ( $ ) - - - - - -
Yield - - - - - -
Reference price ( $ ) 367,090 375,960 373,500 344,870 344,870 344,870
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2016 2017 2018 2019 (e) 2020 (e) 2021 (e)
Debt - - - - - -
Finance 56,4 706 2 101 5 371 6 940 9 882
Operating income (EBITDA) 1 435 2 732 3 110 3 440 3 845 4 013
Leverage
(Debt/EBITDA)
- - - - - -
Capital Expenditure 512 273 383 418 446 450
Free Cash Flow (FCF) 961 1 034 1 812 2 306 2 651 2 819
Book Value Per Share (BVPS) ( $ ) 42,5 57,1 76,3 111 140 171
Cash Flow per Share ( $ ) 12,7 11,3 19,1 29,2 27,5 24,3
Announcement Date 02/09/2017
11:30am
02/08/2018
11:30am
02/06/2019
11:30am
- - -
Balance Sheet Analysis
Assessed data source
© 2019 S&P Global Market Intelligence
Financial Ratios

Size 2019e 2020e
Capitalization 37 702 M $ -
Entreprise Value (EV) 32 331 M $ 30 762 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) 19,7x 15,7x
Capitalization / Revenue 4,85x 4,52x
EV / Revenue 4,15x 3,88x
EV / EBITDA 9,40x 8,41x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,12x 2,46x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) 29,3% 34,7%
Operating Leverage (Delta EBIT / Delta Sales) - 3,71x
Net Margin (Net Profit / Revenue) 25,7% 30,2%
ROA (Net Profit / Asset) 18,8% 17,8%
ROE (Net Profit / Equities) 24,0% 22,5%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   5,37% 5,34%
Cash Flow / Sales 41,1% 36,1%
Capital Intensity (Assets / Sales) 1,37x 1,70x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend